L-DOS47 is the company’s first immunoconjugate-based drug candidate being developed based upon its new DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental
The company said that this marks the first FDA approved starting material from its Chinese subsidiary ANP, and signifies that this facility has been qualified by the FDA.
The move has been facilitated by the start of a collaboration between Benitec and ReNeuron, a UK-based stem cell therapeutics firm. The new program will use Benitec’s ddRNAi
Encenicline is a new alpha 7 agonist currently in Phase III development to treat cognitive impairment in schizophrenia and Alzheimer’s disease (AD). Recently, the company completed patient enrollment
The deal will add two quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, to Pfizer Ireland Pharmaceuticals’ portfolio. Nimenrix is a single dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine
AMG 334 is a fully human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, which is believed to transmit signals that can cause incapacitating pain. A
The funds, provided to the Ontario Institute for Regenerative Medicine (OIRM) 150 stem cell and regenerative medicine scientists, clinicians and engineers, will be used to examine new chronic
TD is caused by prolonged exposure to medications that block dopamine receptors, including antipsychotic drugs and some drugs used to treat nausea. The company said that dopamine is
BGB-3111 is the company’s investigational, oral, highly selective and potent inhibitor of BTK, a critical component of B-cell receptor (BCR) signaling that plays a major role in B-cell
Sickle cell disease (SCD), which is the most common inherited blood disorder in the US, is estimated to affect nearly 100,000 people and the estimated cost of care
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.